PROCEPT BioRobotics Corporation (PRCT)

PROCEPT BioRobotics Corporation is trading at $19.92, down 0.55% on the session. The 50 day average sits at $19.81 and the 200 day at $23.97, which puts the stock in a downtrend. RSI is at 43.5, which reads as weak, and MACD is bullish crossover. Volume is below average.

The nearest support is around $17.12 with resistance near $18.67, so that band frames the current range. Average daily movement is roughly $1.05, or about 5.3% of the share price, which is what any stop placement has to allow for. The overall health score of 35 out of 100 combines a trend score of 23, momentum of 48 and a risk score of 36.

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.